Source: International Congress 2014 – Rationale behind respiratory drug development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Worth, R. Buhl, C. P. Criée, P. Kardos, C. Vogelmeier (Fuerth, Mainz, Bovenden, Frankfurt am Main, Marburg, Germany). Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry. Eur Respir J 2014; 44: Suppl. 58, 929

Member's Comments

No comment yet.

Related content which might interest you: What are common COPD symptoms in a real-life setting? The German DACCORD registry Source: International Congress 2014 – COPD markers Year: 2014 Distribution and outcomes of the new Spanish phenotype-based guideline for COPD Source: International Congress 2014 – COPD exacerbations Year: 2014 Pharmacological treatment of COPD in the on-sint cohort Source: International Congress 2014 – COPD exacerbations Year: 2014 Assessment of patients with COPD according to previous and new GOLD: Which stage in which group? Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 Results of a pulmonary rehabilitation program (PRP) in COPD patients: Differences in outcomes according to currently 2011 GOLD groups Source: International Congress 2014 – Best posters in pulmonary rehabilitation 2 Year: 2014 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Disease progression and changes in risk groups' classification over a period of one year in the GPs based Swiss chronic obstructive pulmonary disease (COPD) cohort Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: A national cross-sectional survey Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Drug treatment in a German real-life COPD cohort (DACCORD) Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Cluster analyses in a sample of COPD patients Source: International Congress 2014 – Best posters in pulmonary rehabilitation 1 Year: 2014 Clinical trials for elderly patients with multiple diseases (CHROMED): A pilot study Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Characteristics and outcomes of GOLD C and D COPD patients Source: International Congress 2014 – Longitudinal studies of respiratory disease Year: 2014 Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 The 2013 updated GOLD strategy: A comparison of the various scenarios Source: International Congress 2014 – Best abstracts in chronic care Year: 2014 Impact of chronic obstructive pulmonary disease (COPD) and patients' absence from work in Greece - the GOLDEN II study Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Validation of the COPD control concept: A UK pilot Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Late Breaking Abstract - Adherence to GOLD recommendations in Italian COPD patients stratified by GOLD groups A–D: The MISTRAL study Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017 As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014